Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Acute major bleeding episode that required urgent reversal of anticoagulation; defined by at least one of the following:~   * Acute bleeding that was potentially life-threatening, or~  * Acute bleeding associated with a fall in hemoglobin level by ≥2 grams/deciliter (g/dL), or~  * Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline hemoglobin was available, or~  * Acute bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial.~2. If bleeding was intracranial or intraspinal, the participant must have undergone a head computed tomography (CT) or magnetic resonance imaging (MRI) scan demonstrating the bleeding.~3. Participant received or was believed to have received one of the following within 18 hours prior to andexanet administration: apixaban, rivaroxaban, edoxaban, or enoxaparin.~4. For participants with intracranial bleeding, there must be a reasonable expectation that andexanet treatment will commence within 2 hours of the baseline imaging evaluation.~Key Exclusion Criteria:~1. The participant was scheduled to undergo surgery in less than 12 hours, with the exception of minimally invasive surgery/procedures.~2. Participant with an intracerebral hemorrhage that had any of the following:~   * Glasgow coma score \<7, or~  * Intracerebral hematoma \>60 cubic centimeters as assessed by CT or MRI~3. Participants with visible, musculoskeletal or intra-articular bleeding as their qualifying bleed.~4. Expected survival of less than 1 month.~5. Recent history (within 2 weeks) of a diagnosed thrombotic event as follows: venous thromboembolism, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris hospitalization or severe peripheral vascular disease within 2 weeks prior to Screening.~6. Severe sepsis or septic shock at the time of Screening.~7. Pregnant or a lactating female.~8. Participant received any of the following drugs or blood products within 7 days of Screening:~   * Vitamin K antagonist~  * Dabigatran~  * Prothrombin Complex Concentrate (PCC) products or recombinant factor VIIa (rfVIIa)~  * Whole blood, plasma fractions~9. Treated with an investigational drug \<30 days prior to Screening.~10. Planned administration of PCC, fresh frozen plasma or rfVIIa from Screening until within 12 hours after the end of the andexanet infusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Andexanet (Type: EXPERIMENTAL): Participants received andexanet as an intravenous bolus administered over \~15 to 30 minutes, followed immediately by a continuous infusion administered over \~120 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).